Piramal Critical Care outlines sustainability commitment

Published: 18-Nov-2022

The FY 21-22 report articulates PPL’s ESG journey and integrating sustainability practices across all its businesses, including PCC


Piramal Critical Care (PCC) has integrated its sustainability framework with its strategy as well as daily business practices. 

As part of the endeavour, PCC’s Environment, Social and Governance (ESG) policy covers sustainable and environment-friendly practices across energy and waste management, climate change management, greenhouse gas (GHG) reduction, water stewardship, supplier assessment, and integration of sustainability into the company’s operations to ensure continual improvement in the company’s performance and employee engagement. PCC is the complex hospital generics business under Piramal Pharma.

PCC’s commitment towards sustainability dovetails into the overall objective of integrating sustainable practices across all businesses under PPL, as articulated in PPL’s Sustainability Report FY 21–22. 

Peter DeYoung, CEO, Global Pharma, said: “Our growth trajectory is guided by responsible business principles. Our second Sustainability Report is a manifestation of the progress of this journey and provides our stakeholders with a transparent view of our ESG performance.”

Under the ESG strategy, one of the key focus areas for Piramal is sustainability initiatives.  The company has set time-bound targets to review its energy and GHG emission profile and develop a decarbonisation plan to reduce Scope 1, 2 and 3 GHG emissions. The company is also striving to maximise the green cover at operating sites. The company is also taking initiatives towards reducing energy consumption and managing energy systems by implementing energy-efficient equipment and appliances, wherever relevant. Water management, zero incinerable hazardous waste to landfill and non-hazardous waste disposal are also priority areas of the company’s ESG plans. Piramal’s facilities utilise techniques that are sustainable and environmentally conscious. 

Climate change management

The efforts and actions are continually focused on reducing Scope 1 and 2 emissions. GHG emissions are mainly generated directly through natural gas consumption used to heat the facilities, create process steam and indirectly through the purchase of electricity.  A closed manufacturing system in conjunction with an automated packaging line at the Bethlehem facility is designed to eliminate/reduce open handling. These measures help to address GHG emissions and minimise negative ecological effects. The company monitors and control air emissions at various facilities, ensuring they are within the permissible regulatory limits as per site environmental permits.

Water stewardship

The company is exploring new technologies and aiming to develop water-conservation solutions to reduce freshwater usage. The company plans to conduct a water-use audit for all sites, allowing us to identify areas for improved efficiency, reduced usage, and possible recycling options. During FY 2021–22, total water usage by manufacturing locations was reduced by 8%.

Key environmental highlights from the Piramal Pharma Sustainability Report FY21–22

  • Increased the use of renewable energy by replacing coal with bio briquette, installing solar roof panels, LED lighting in place less efficient technology, and using hydroelectric power 
  • Controlled emissions using process controls and technologies, including nitrogen blanketing, efficient gas scrubbing systems, multistage condensers, bag filters, and electrostatic precipitators 
  • Implemented tree plantation programmes across locations; manufacturing facilities currently have more than 82,000 trees 
  • Drove technology absorption for energy efficiency and greenhouse gases

You may also like